{"filing":{"accession_number":"0001654954-26-007990","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"a7351s.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007990/a7351s.htm"},"events":[{"id":30781,"run_id":28221,"accession_number":"0001654954-26-007990","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This 6-K discloses European Commission approval of Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for first-line treatment of HER2-positive metastatic breast cancer, based on positive Phase III DESTINY-Breast09 trial results showing 44% reduction in disease progression or death risk. While this is a regulatory/product milestone rather than a discrete financial event, M\u0026A activity, or governance matter, it is material to investors as it represents a significant commercial expansion of a key oncology asset with substantial market potential, supported by a $100 million milestone payment from AstraZeneca to Daiichi Sankyo. The event is operational in nature—a regulatory approval and product launch milestone—rather than fitting the specific categories of earnings, M\u0026A, or financial obligations.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33491,"accession_number":"0001654954-26-007990","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This 6-K discloses European Commission approval of Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for first-line treatment of HER2-positive metastatic breast cancer, based on positive Phase III DESTINY-Breast09 trial results showing 44% reduction in disease progression or death risk. While this is a regulatory/product milestone rather than a discrete financial event, M\u0026A activity, or governance matter, it is material to investors as it represents a significant commercial expansion of a key oncology asset with substantial market potential, supported by a $100 million milestone payment from AstraZeneca to Daiichi Sankyo. The event is operational in nature—a regulatory approval and product launch milestone—rather than fitting the specific categories of earnings, M\u0026A, or financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:27:39.934517+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01"}]}